BrightSpring Health Services, Inc. Common Stock
BTSG
$56.78
+0.32%
BrightSpring Health Services, Inc. is a home and community-based healthcare services platform that delivers complementary pharmacy and provider services to complex patient populations, operating primarily across Medicare, Medicaid, and commercially insured segments through its Pharmacy Solutions and Provider Services divisions. The company occupies a distinctive position as an integrated, scaled platform in the fragmented home-and-community care market, with its Pharmacy Solutions segment generating the majority of revenue and serving as the engine of its growth narrative. The current investor debate centers on the durability of its specialty pharmacy momentum — sales in that business are up roughly 30% — against a roughly $200 million revenue headwind from Inflation Reduction Act (IRA) drug-pricing provisions that management contends is largely offset by operational efficiencies. The company's recent divestiture of its ResCare Community Living business to Sevita signals a strategic sharpening toward higher-growth core operations, while its relatively recent public listing (January 2024) means the market is still forming its long-term view on the name.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$56.78
Related headlines
Investment Opinion: Should I buy BTSG Today?
The synthesized recommendation is Buy, anchored by a strong buy consensus (recommendation mean 1.18) and an average analyst target of $78.94, implying 39% upside from the current price of $56.78. The core thesis is that BrightSpring is a growth-oriented healthcare platform with accelerating revenue (25.56% YoY), expanding margins, and a reasonable forward valuation of 24.92x earnings, which is supported by a 37% expected earnings growth implied by the trailing-to-forward PE compression. The recent pullback (-14.29% over three months) offers an attractive entry point for long-term investors willing to tolerate volatility.
Supporting evidence includes: 1) Revenue growth of 25.56% YoY in Q1 2026, with specialty pharmacy up ~30%; 2) Gross margin expansion to 13.34% from 11.76%, and net margin improvement to 4.12% from 1.03%; 3) Solid free cash flow of $412.12M TTM, with $101.40M in Q1 2026; 4) Forward PE of 24.92x, which is below the trailing PE of 39.84x and in the middle of its historical range, suggesting the stock is not overvalued relative to its growth. The PS ratio of 0.59x and EV/Sales of 0.94x are low for a company with this growth profile, though typical for pharmacy distributors.
Key risks that could invalidate the thesis include: 1) The $200M IRA headwind not being fully offset, which could pressure margins; 2) High leverage (D/E of 1.44) and sensitivity to interest rates; 3) Deceleration in specialty pharmacy growth or competitive pressures. The rating would upgrade to a stronger Buy if the stock reclaims the $62-$64 area and forward PE remains below 25x, or downgrade to Hold if revenue growth falls below 20% or if the IRA impact exceeds expectations. Relative to its history and peers, the stock appears fairly valued to slightly undervalued, with the potential for multiple expansion if execution continues.
Sign up to view all
BTSG 12-Month Price Forecast
The forward-looking view is bullish, supported by accelerating revenue growth, expanding margins, and a reasonable valuation relative to growth. The analyst consensus is overwhelmingly positive, with a strong buy rating and a target price implying significant upside. However, the high beta (1.85) and recent negative momentum (-14.29% over three months) introduce near-term uncertainty. The key risk is the IRA headwind, but management's track record of offsetting it provides some confidence. I would upgrade to high confidence if the stock reclaims $62-$64 and Q3 earnings show continued margin expansion; I would downgrade to neutral if revenue growth falls below 20% or if the IRA impact exceeds expectations.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $78.94 and implied upside of +39.0% versus the current price.
Average Target
$78.94
0 analysts
Implied Upside
+39.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $90
Analyst target range
Coverage is robust, with 17 analysts covering BrightSpring and a consensus recommendation of "strong_buy" (recommendation mean of 1.18 on a scale where 1 is a strong buy). The average target price is $78.94, which implies roughly 39% upside from the current price of $56.78 — a strongly bullish consensus. The consensus EPS estimate of $5.45 and revenue estimate of $30.94 billion for the forward period underpin this optimism, and the sentiment clearly leans bullish given the strong_buy rating and the substantial gap between the current price and the average target. The target range is relatively wide, spanning from a low of $70.00 to a high of $90.00 — a spread of $20, or roughly 25% of the average target — which signals meaningful dispersion in analyst views and higher uncertainty. The high target of $90.00 implies roughly 58.5% upside and likely assumes accelerating specialty pharmacy growth, successful IRA headwind mitigation, continued margin expansion, and possibly multiple re-rating as the company proves its earnings power. The low target of $70.00 still implies about 23.3% upside, suggesting even the most cautious analysts see the stock as undervalued, though that scenario likely prices in slower growth, IRA pressure, or competitive erosion in pharmacy. Institutional ratings show a consistent pattern of reaffirmations rather than upgrades or downgrades — Morgan Stanley, KeyBanc, Wells Fargo, UBS, BofA, BTIG, TD Cowen, and Goldman Sachs all maintained Overweight or Buy ratings between May and July 2026 — indicating stable, high-conviction bullish coverage with no recent downgrades, which is a constructive signal for the stock's risk/reward profile.
Bulls vs Bears: BTSG Investment Factors
The bull case currently has stronger evidence, supported by accelerating revenue growth of 25.56%, expanding margins, a strong buy consensus with 39% upside, and a reasonable forward PE of 24.92x. However, the bear case is not without merit, highlighted by negative recent momentum (-14.29% over three months), high leverage (D/E of 1.44), and the $200M IRA headwind. The single most important tension is whether the specialty pharmacy growth (~30%) can sustainably offset the IRA pressure and drive continued margin expansion; if it can, the stock is likely undervalued; if not, the premium EV/EBITDA multiple could compress. The market appears to be pricing in successful execution, so any disappointment could lead to a sharp re-rating given the high beta.
Bullish
- Revenue growth accelerating to 25.6%: Q1 2026 revenue of $3.6137B grew 25.56% YoY, up from roughly 18% growth in mid-2025, with sequential expansion every quarter from $3.1477B in Q2 2025 to $3.6137B in Q1 2026. This acceleration is driven by specialty pharmacy sales up ~30%, signaling durable share gains in a fragmented home-and-community care market.
- Margin expansion demonstrates operating leverage: Gross margin expanded to 13.34% in Q1 2026 from 11.76% a year earlier, a ~158 basis point improvement, while operating margin rose to 3.36% from 1.76%. Net income surged to $148.77M (4.12% margin) from $29.54M (1.03% margin), showing that scale is translating into meaningful profitability gains.
- Strong analyst consensus with 39% upside: All 17 covering analysts rate the stock a strong buy (recommendation mean 1.18), with an average target price of $78.94 implying ~39% upside from $56.78. Even the lowest target of $70.00 implies ~23% upside, and no downgrades occurred between May and July 2026, indicating stable high-conviction support.
- Attractive forward valuation at 24.9x: The forward PE of 24.92x represents a ~37% compression from the trailing PE of 39.84x, implying substantial expected earnings growth. With consensus EPS of $5.45 and revenue of $30.94B, the stock trades at just 0.59x sales and 0.94x EV/Sales, low absolute multiples for a company growing revenue 25%+.
Bearish
- Recent momentum sharply negative: Despite a 108.37% one-year gain, the stock is down 4.30% over the past month and 14.29% over the past three months, underperforming SPY by 3.34 and 16.29 percentage points respectively. This deceleration from a 52-week high of $73.75 to $56.78 suggests waning momentum and potential further consolidation.
- High leverage and thin margins: Debt-to-equity stands at 1.44, and net margin is only 4.12% despite recent improvement. Interest coverage of roughly 3.15x and cash flow-to-debt of 0.046 indicate that external financing conditions remain important, and any rise in rates could pressure profitability.
- IRA headwind of $200M: The Inflation Reduction Act drug-pricing provisions create a roughly $200M revenue headwind that management claims is largely offset by operational efficiencies. However, if offsets prove insufficient, this could materially impact forward revenue and earnings, especially given the thin margins.
- Elevated valuation on EV/EBITDA: The EV/EBITDA of 22.21x is at a premium to typical distribution-oriented peers, leaving limited room for execution missteps. With a beta of 1.85, the stock is 85% more volatile than the market, amplifying drawdown risk in adverse scenarios.
BTSG Technical Analysis
BrightSpring is in a powerful primary uptrend, with the stock up 108.37% over the past year versus a 15.01% gain for SPY — a relative strength advantage of 93.36 percentage points. At a current price of $56.78, the stock sits at roughly 64.5% of its 52-week range (52-week low of $26.28, high of $73.75), meaning it has given back a meaningful portion of its highs but remains far above its lows. This positioning suggests a stock in a healthy but no-longer-euphoric phase: momentum has cooled from the peak, yet the structural uptrend remains intact, and the 47.86% YTD gain confirms buyers have controlled the tape for most of 2026. Recent momentum, however, has turned negative and is diverging sharply from the longer-term trend: the stock is down 4.30% over the past month and 14.29% over the past three months, underperforming SPY by 3.34 and 16.29 percentage points respectively over those windows. This 1-month and 3-month weakness against a 1-year gain of 108.37% and a 6-month gain of 37.78% signals a deceleration phase — likely a consolidation or corrective pullback within a larger uptrend rather than a full trend reversal, though the magnitude of the 3-month underperformance warrants caution. The stock's beta of 1.85 means it is 85% more volatile than the market, amplifying both the upside and the drawdown risk and arguing for smaller position sizing. Key technical levels are clear: resistance sits at the 52-week high of $73.75 (a breakout above which would reassert the uptrend and likely target new highs), while support rests near the 52-week low of $26.28, with the more immediate battleground being the recent $56-$58 congestion zone. The maximum drawdown of -22.37% and a short ratio of 3.58 (suggesting some short interest) mean a breakdown below $56 could accelerate selling, while a reclaim of the $62-$64 area would signal the correction is ending.
Beta
1.85
1.85x market volatility
Max Drawdown
-22.4%
Largest decline past year
52-Week Range
$26-$74
Price range past year
Annual Return
+108.4%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | -4.3% | -0.5% |
| 3m | -14.3% | +2.3% |
| 6m | +37.8% | +16.6% |
| 1y | +108.4% | +14.8% |
| ytd | +47.9% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
Revenue is growing robustly: the most recent quarter (Q1 2026, ended 2026-03-31) delivered $3.6137 billion in revenue, up 25.56% year-over-year from $2.8781 billion in Q1 2025. The multi-quarter trend shows consistent sequential expansion — from $3.1477 billion in Q2 2025 to $3.3341 billion in Q3 2025 to $3.5506 billion in Q4 2025 to $3.6137 billion in Q1 2026 — with the YoY growth rate accelerating from roughly 18% in mid-2025 to over 25% in the latest quarter. Segment data shows Commercial Insurance contributing $1.0143 billion and Medicaid $405.7 million, with the specialty pharmacy business (up ~30%) as the clear growth driver, though the roughly $200 million IRA headwind is a watch item for forward revenue. This accelerating top-line trajectory, if sustained, supports the bull case that BrightSpring is a share-gainer in a structurally growing home-and-community care market. Profitability is real but thin and improving: Q1 2026 net income was $148.77 million on a net margin of 4.12%, up sharply from $29.54 million (1.03% margin) in Q1 2025, while gross margin expanded to 13.34% from 11.76% a year earlier. Operating income rose to $121.45 million (3.36% operating margin) from $50.74 million (1.76%), and EBITDA grew to $160.54 million from $92.90 million — demonstrating meaningful operating leverage. Gross margins in the low-to-mid teens are typical for pharmacy-heavy healthcare distributors, so the key story is margin expansion (gross margin up ~158 basis points YoY) rather than absolute margin level, and the trend is clearly favorable. The balance sheet carries meaningful leverage but is manageable: debt-to-equity stands at 1.44, the current ratio is a healthy 1.57, and ROE has climbed to 10.17% with ROA at 4.88%. Free cash flow is solid and growing — TTM FCF of $412.12 million, with Q1 2026 FCF of $101.40 million and operating cash flow of $122.94 million — and the company holds $888.80 million in cash after a large investing inflow (including the ResCare divestiture). With interest coverage of roughly 3.15x and cash flow-to-debt of 0.046, the company generates enough internal cash to fund capex ($21.54 million in Q1 2026) and modest buybacks ($60 million repurchased), though the elevated leverage means external financing conditions still matter.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+25.6%
YoY Comparison
Gross Margin
13.3%
Latest Quarter
Free Cash Flow
$412118000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Because BrightSpring is profitable (Q1 2026 net income of $148.77 million; trailing EPS of $0.0251 on a TTM basis per key metrics), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 39.84x versus a forward PE of 24.92x — a roughly 37% compression that implies the market expects substantial earnings growth, consistent with consensus EPS estimates of $5.45 for the forward period. The very low trailing EPS figure in the key metrics (reflecting GAAP dilution and one-time items) makes the forward PE the more economically meaningful anchor, and at ~25x forward earnings the stock is not obviously expensive for a company growing revenue 25%+ with expanding margins. On peer comparison, the stock trades at a PS ratio of 0.59x and an EV/Sales of 0.94x — low absolute multiples that reflect the thin-margin, high-revenue nature of pharmacy distribution, and a PB ratio of 4.05x. Relative to the broader healthcare information services industry, the forward PE of ~25x and EV/EBITDA of 22.21x sit at a premium to typical distribution-oriented peers but a discount to high-growth healthcare technology names; the market appears to be pricing BrightSpring as a hybrid — a scaled distributor with improving profitability rather than a pure-play tech platform. The premium is arguably justified by the 25.56% revenue growth, expanding gross margins, and the specialty pharmacy momentum, though the 22.21x EV/EBITDA leaves limited room for execution missteps. Historically, the stock's own valuation band has compressed dramatically as earnings have grown: PE was 53.22x in Q4 2024, 30.15x in Q1 2025, 42.12x in Q2 2025, 27.37x in Q3 2025, 24.64x in Q4 2025, and 14.59x in Q1 2026 — showing the multiple has fallen even as the stock price rose, meaning earnings growth has outpaced price appreciation. The PS ratio, by contrast, has risen from 1.12x in Q4 2024 to 2.41x in Q1 2026, indicating the market has re-rated the revenue base upward. The current forward PE of ~25x sits in the middle of this historical range, suggesting the stock is neither at a valuation extreme nor a bargain — the investment case rests on continued earnings delivery rather than multiple expansion.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are centered on the company's leveraged balance sheet and thin margins. With debt-to-equity at 1.44 and interest coverage of approximately 3.15x, BrightSpring carries a meaningful debt burden that could constrain flexibility if interest rates rise or cash flows weaken. Net margin, while improving to 4.12% in Q1 2026, remains thin, leaving little cushion for unexpected cost increases or revenue shortfalls. Additionally, the company faces a $200M IRA revenue headwind that management expects to offset through efficiencies, but any shortfall could disproportionately impact profitability given the low margin base. Revenue concentration in the Pharmacy Solutions segment, which generates the majority of revenue, adds another layer of risk if specialty pharmacy growth decelerates.
Market and competitive risks include valuation compression and high volatility. The stock trades at a premium EV/EBITDA of 22.21x compared to distribution peers, which leaves limited room for error; if growth slows or margins contract, the multiple could contract sharply. The beta of 1.85 means the stock is 85% more volatile than the market, so it is highly sensitive to macro shifts, such as changes in healthcare policy or interest rates. Competitive pressures in the specialty pharmacy space could erode BrightSpring's 30% growth rate, and the wide analyst target range ($70-$90) reflects uncertainty about sustainability. Recent news highlights the IRA headwind and the need to watch for competitive pressures, which could trigger a sell-off if growth metrics disappoint.
The worst-case scenario involves a combination of factors: the IRA headwind proving larger than anticipated, specialty pharmacy growth slowing significantly, and margin expansion stalling. This could lead to earnings misses, analyst downgrades, and multiple compression. In such a scenario, the stock could retest its 52-week low of $26.28, representing a decline of approximately 53.7% from the current price of $56.78. Even a more moderate bear case, aligning with the analyst low target of $70.00, implies upside, but that assumes no major deterioration. A realistic downside could see the stock fall to the $40-$45 range, a decline of 21-30%, if growth decelerates and the market re-rates the stock to a lower multiple. The maximum drawdown of -22.37% over the past year shows that such declines are possible in a short period.
FAQ
The key risks for BTSG, ranked by severity, are: 1) Financial risk: high leverage with a debt-to-equity of 1.44 and thin net margin of 4.12%, leaving little cushion for unexpected costs or revenue shortfalls. 2) Regulatory risk: the $200M IRA headwind could be larger than anticipated or offsets may not fully materialize, directly impacting revenue and profitability. 3) Competitive risk: specialty pharmacy growth of ~30% may decelerate due to competition, which would undermine the growth narrative and likely compress the premium EV/EBITDA multiple of 22.21x. 4) Market risk: the high beta of 1.85 means the stock is highly sensitive to macro shifts, and recent momentum is negative (-14.29% over three months), increasing the chance of further downside. Additionally, the wide analyst target range ($70-$90) indicates uncertainty, and any earnings miss could trigger a sharp sell-off.
The 12-month forecast for BTSG includes three scenarios: Bull case (30% probability) targets $85-$90, assuming successful IRA mitigation, sustained 30% specialty pharmacy growth, and multiple expansion. Base case (50% probability) targets $75-$82, assuming consensus estimates are met with revenue growth of 20-25% and gradual margin improvement. Bear case (20% probability) targets $45-$55, assuming IRA headwind exceeds expectations, growth decelerates, and margins stall. The base case is most likely, with the key assumption that BrightSpring continues to offset the IRA headwind and delivers on its growth trajectory. The average analyst target of $78.94 aligns with the base case, implying ~39% upside from the current price.
BTSG appears fairly valued to slightly undervalued based on its growth prospects. The forward PE of 24.92x is a ~37% discount to the trailing PE of 39.84x, implying expected earnings growth, and it sits in the middle of its historical range (from 14.59x to 53.22x over the past two years). The PS ratio of 0.59x and EV/Sales of 0.94x are low in absolute terms, typical for pharmacy distributors, but the EV/EBITDA of 22.21x is at a premium to peers, reflecting the market's expectation of continued margin expansion. Compared to the broader healthcare information services industry, the valuation is a premium for a distributor but a discount to high-growth tech names. The market is pricing in successful execution of the specialty pharmacy growth and IRA mitigation; if these falter, the multiple could compress.
From a risk/reward perspective, BTSG appears attractive for investors with a long-term horizon and tolerance for volatility. The stock trades at $56.78, with an average analyst target of $78.94 implying ~39% upside, and a strong buy consensus from 17 analysts. The company is growing revenue at 25.56% YoY with expanding margins, and the forward PE of 24.92x is reasonable relative to that growth. However, the high beta of 1.85 and recent negative momentum (-14.29% over three months) mean short-term risks are elevated. The biggest downside risk is the $200M IRA headwind, which could pressure margins if not fully offset. Overall, it is a good buy for growth-oriented investors who can withstand a potential 20-30% drawdown in a bear scenario, but it may not be suitable for risk-averse or short-term traders.
BTSG is more suitable for long-term investment, given its growth stage, high volatility (beta 1.85), and lack of dividend (payout ratio 0). The company is still in a growth phase, with revenue expanding at 25.56% YoY and margins improving, but earnings visibility is moderate due to the IRA headwind and competitive pressures. The stock's high beta and recent negative momentum make it risky for short-term trading, as it can swing widely. A long-term investor with a horizon of at least 2-3 years could benefit from the compounding effect of revenue growth and margin expansion, as well as potential multiple re-rating. A minimum suggested holding period is 18-24 months to ride out volatility and allow the company to prove its ability to sustain growth and mitigate headwinds.